Project Profile:An offshore branding company commissioned Chinese factories to produce OTC specialized drugs. The client had previously processed part of the FDA drug declaration through other service providers, but the registration of brand parties as pharmaceutical facilities was not accurately reflected in the production role of Chinese factories. Clients want to clarify the differences between existing records and the actual supply chain before revising the relevant information.

The point in this case is not to apply for another number.Brand parties, physical production facilities, NDC Labeler Code holders and project submitting parties have different responsibilities and should check roles based on actual activity before processing registration and listing.

How did you find out?

ALL REG holds on-line meetings with clients to learn about branding, commissioning and product arrangements to be sold in the United States, and to explain to clients the difference between OTC Monographing Drug Facility Registration, Labeler Code, NDC listing and the annual fee for OMUFA facilities. Once the old records were reconciled, the focus of the project shifted to allowing FDA declarations to accurately reflect the activities of foreign brand parties and Chinese surrogates.

How can facilities and business roles be revised?

  1. To assist Chinese factories in obtaining D—U—N—S codes corresponding to their production facilities, to collate information on actual production activities and to register the appropriate pharmaceutical facilities according to their surrogate production roles.
  2. Processing of registration records for pharmaceutical facilities that had previously been excluded, in conjunction with actual activities of foreign brand parties.
  3. Reconciling the Labeler Code, which is already in the possession of both parties, to process the code matters applicable to the plant and to revise the brand-side information to reflect the role of the owner brand dealer.

FDA states that only facilities engaged in the manufacture, repackaging, relabelling or recycling of appropriate medicines shall be registered; Labeler Code is a different matter from the registration of facilities. The manner of submission depends on the actual operation of the enterprise and the current record.

What about modern working relationships?

(a) The team reorganized the branding product, Drug Listing, so that the listing information reflects the actual production role of Chinese factories; At the same time, the plant’s own NDC and listing responsibilities are applied to the products it produces. It's not putting the brand on the same NDC again. FDA has made it clear in its listing relationship between its own brand distributors and its surrogates that even if brand parties use their own NDC listings, the surrogates will still have to meet the applicable product listing obligations.

Done what?

Based on the project history provided by the client, ALREG completed the revision of the relevant business roles, facilities registration, Labeler Code and product listing to make the declaration more accurately reflect the commissioned production relationship. Clients, factories, products, serial numbers or submission of applications are not disclosed here, nor are they described as FDA approvals of products, determinations of full compliance with enterprises or assurance of the results of similar projects.

Annual fee for OTC Monograph Facilities

The annual fee cannot be judged solely on the basis of whether a brand is registered or NDC. The OMUFA facility fee for FDA is for eligible OTC specialized pharmaceutical production facilities, including qualified surrogate facilities; The activity of the facility, the year to which it applies and the FDA fee records should be reconciled. In the present case, no notice of actual charges or deductions were made public, and therefore no claim was made that an annual fee had been waived or saved.

Checklist for similar items

  • Identify the activities of brand parties, actual production plants, packaging/labelling enterprises and United States sellers.
  • Check facility registrations, D—U—N—S, Labeler Code, NDC, Drug Listing and product labels on a case-by-case basis to avoid inconsistencies between the main information of the different systems.
  • Confirm OTC’s routing of application, OMUFA costs for production facilities and annual renewal responsibilities; Listing or NDC does not amount to listing permission.

Official sources and reconciliation dates

Source: Project history provided by the client to ALREG; The name of the client and the factory is anonymous. First-time publication and reconciliation of regulatory information: 2026-10-29. The obligation to make a specific declaration is based on the actual product, the activities of the enterprise and the current requirements of the FDA.

Consultation drug registration and listing pathView pricing and order online ↗ View Drugs FDA Compliance Service